Avila Jorge, Degirmenci Huseyin Berk, Contreras Chavez Pamela, Battinelli Elisabeth M, Fleisher Jorge
Department of Medicine, St. Elizabeth's Medical Center, Tufts University School of Medicine, Boston, MA, USA.
Dana Farber Cancer Institute at St. Elizabeth's Medical Center, Boston, MA, USA.
Case Rep Hematol. 2023 Mar 13;2023:7877536. doi: 10.1155/2023/7877536. eCollection 2023.
The coronavirus disease 2019 (COVID-19) pandemic has affected millions of people around the world. Vaccination against COVID-19 has been approved for the following three vaccines in the United States: Pfizer-BioNTech, Moderna, and Janssen. Hematological complications of vaccination have been reported in the literature but remain as a rare phenomenon. We present the case of a patient who developed severe thrombocytopenia within twenty-four hours following the Pfizer-BioNTech vaccination. Commonly encountered differentials including heparin-induced thrombocytopenia and common viral etiologies were ruled out, and other causes such as drug reactions deemed unlikely as the etiology of this presentation after a broad workup. Nucleocapsid antibodies against COVID-19 were found to be positive which indicated that vaccination was at least the second encounter with this virus for our patient, which has been reported previously as the cause of immune thrombocytopenia (ITP), and this might be the culprit for sudden onset. He responded to the first-line ITP treatment with corticosteroids and intravenous immunoglobulin (IVIG) as evidenced by the fast recovery of platelet count and lack of recurrence of thrombocytopenia.
2019年冠状病毒病(COVID-19)大流行已影响全球数百万人。在美国,以下三种疫苗已获批用于COVID-19疫苗接种:辉瑞-生物科技公司疫苗、莫德纳疫苗和杨森疫苗。文献中已报道了疫苗接种后的血液学并发症,但仍然是一种罕见现象。我们报告一例在接种辉瑞-生物科技公司疫苗后24小时内出现严重血小板减少症的患者。常见的鉴别诊断包括肝素诱导的血小板减少症和常见病毒病因均被排除,经过广泛检查后,其他原因如药物反应也不太可能是该病例的病因。发现针对COVID-19的核衣壳抗体呈阳性,这表明接种疫苗至少是我们的患者第二次接触这种病毒,此前已有报道称这是免疫性血小板减少症(ITP)的病因,这可能是突然发病的罪魁祸首。他对一线ITP治疗(使用皮质类固醇和静脉注射免疫球蛋白(IVIG))有反应,血小板计数迅速恢复且血小板减少症未复发证明了这一点。